Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Inc. (GILD) stock to Outperform rating, as announced on July 8, 2024, according to Finviz. Earlier, on May 1, 2024, Maxim Group had reiterated the stock to Buy, setting a price target of $85. for GILD ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

Resistance levels have broken higher and unless the stock reverses lower and below support levels again short positions look risky. Buy GILD slightly over n/a, target n/a, Stop Loss @ 0 Details If n/a ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc (NASDAQ:GILD), sold 29,357 shares of the company on 12, 2024 ...